Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish

Context Therapeutics Inc. (NASDAQ:CNTX) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. A sharp stock selloff tied to early clinical data has drawn a series of analysts defending the shares as oversold. The stock is down nearly 60% year-to-date.

On June 16, 2026, Maxim analyst Jason McCarthy lowered the firm’s price target on Context Therapeutics Inc. (NASDAQ:CNTX) to $4 from $8 while maintaining a “Buy” rating. The cut followed the company’s interim Phase 1a data for CTIM-76 in platinum-resistant ovarian cancer, but McCarthy called the sharp negative stock reaction an overreaction, noting the study remains exploratory and focused on learning about the drug’s pharmacokinetic (PK) profile, dosing, safety, and initial efficacy.

That view echoed commentary from a day earlier. On June 15, 2026, Jones Research called the selloff in Context Therapeutics Inc. (NASDAQ:CNTX) a buying opportunity, describing the Phase I update of CTIM-76 in CLDN6-positive solid tumors as encouraging. The firm pointed to a 29% overall response rate in platinum-resistant ovarian cancer patients who had a median of seven prior therapies, contrasting that with Zymeworks’ ZW191, tested in patients with a median of three prior therapies. Jones kept a “Buy” rating and $7 price target. Shares fell 47%, or 65 cents, to 74 cents that afternoon, TheFly reported.

On June 15, 2026, H.C. Wainwright analyst Emily Bodnar noted that CTIM-76 data indicated competitive activity versus peers despite a challenging patient population, while reiterating a “Buy” rating and $5 price target on Context Therapeutics Inc. (NASDAQ:CNTX).

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, including CTIM-76, CT-95, and CT-202, targeting CLDN6, MSLN, and Nectin-4 respectively.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.